Policy / Pricing Trump backs psychedelics for mental health in new executive order Pharmaceutical TechnologyTrump's executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field.Policy / PricingNeuroscienceRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaceutical Technology Trump’s executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field. Policy / PricingNeuroscienceRead full story Post navigation Previous: UCB to purchase Neurona and NRTX-1001 for $1.15bnNext: AZ is three for three with COPD hope tozorakimab Related Stories Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged pharminent May 13, 2026 Policy / Pricing EU agrees plan to tackle essential medicine shortages pharminent May 12, 2026 Policy / Pricing 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) pharminent May 12, 2026
